---
title: CRO Daily News — June 22, 2026
slug: daily-news-2026-06-22-cro
site: cro
post_kind: news
byline: BioBM
last_updated: 2026-06-23T00:00:12.763Z
---

### FDA Streamlines Early-Stage IND Submissions and Late-Stage Trial Evidence Standards
- FDA proposes Expedited IND pilot program enabling drug sponsors to partner with academic medical centers and contract research organizations to shorten pre-IND timelines and reduce clinical holds.
- New Phase 1 CMC guidance clarifies phase-appropriate manufacturing data requirements, potentially saving sponsors 6–12 months of development time before first-in-human trials.
- FDA revised substantial-evidence guidance to permit reliance on one rigorous pivotal trial plus confirmatory data for drug approval, reflecting advances in biological understanding and data availability.

**Operational Impact**

CROs offering Phase 1 regulatory strategy and IND preparation services can now position expedited IND partnerships as a core offering, while those supporting late-stage trial design should prepare clients for single-pivotal-trial pathways under the revised effectiveness guidance.

*Source: [FDA What's New Drugs RSS](https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development)*

## References

1. [FDA What's New Drugs RSS — FDA Streamlines Early-Stage IND Submissions and Late-Stage Trial Evidence Standards](https://www.fda.gov/industry/fda-actions-accelerate-and-modernize-early-and-late-stage-clinical-development)

Source: https://cro.directory/posts/daily-news-2026-06-22-cro